Low class–switched memory B cells predict the need for continued immunoglobulin replacement following B cell reconstitution after rituximab: a case series and review of the literature

[1]  W. Mccune,et al.  Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy , 2017, Current opinion in rheumatology.

[2]  Katrina L. Randall.  Rituximab in autoimmune diseases. , 2016, Australian prescriber.

[3]  Deborah A. Bowen,et al.  Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes , 2015, Cancer.

[4]  V. Bonagura,et al.  Rituximab and immune deficiency: case series and review of the literature. , 2014, The journal of allergy and clinical immunology. In practice.

[5]  A. Zelenetz,et al.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. , 2013, Clinical lymphoma, myeloma & leukemia.

[6]  K. Ishizawa,et al.  Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis , 2010, International journal of hematology.

[7]  J. Friedberg,et al.  B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. , 2007, Clinical immunology.

[8]  M. Lindorfer,et al.  Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis , 2007, Nature Clinical Practice Rheumatology.

[9]  T. Koike,et al.  Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non‐Hodgkin lymphoma , 2006, European journal of haematology.

[10]  M. Pescovitz.  Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  D. Maloney,et al.  Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.